Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01312792
Other study ID # PR-10025
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2010
Est. completion date December 2013

Study information

Verified date June 2018
Source International Centre for Diarrhoeal Disease Research, Bangladesh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators Study Hypothesis is introduction of modified IMCI guideline for managing severe pneumonia in first level health facilities will result in 40% increase in the appropriate management (appropriate case management at the first level facility and referral compliance by the caregivers) of severe pneumonia cases in the intervention arm compared to the comparison arm.


Description:

The IMCI was implemented in Bangladesh in 2001. Bangladesh adapted the generic IMCI clinical guidelines which recommend that children with one or more danger signs, or any other severe condition, as identified by the health worker of the first level facility will be referred urgently. Although the quality of care achieved in ten IMCI facilities in Matlab, Bangladesh was assessed as high ( El Arifeen 2004) the rates of compliance with referral found to be low. In 2002-03 the compliance rates were less than 37% and had decreased to 17% by the end of 2003 (El Arifeen S, unpublished data). In many settings, children who are referred do not actually attend hospital, which severely limits their appropriate care. This is mainly because the higher level facilities are geographically inaccessible; financial and social constraints also prevent care givers to comply with the referral advice.

The Govt of Bangladesh is presently planning to modify the current IMCI guideline. The modified guideline recommends that treatment of all severe pneumonia cases without danger signs unless there is another severe classification will be done at the first level facility. In 2004 the Govt. of Bangladesh in collaboration with ICCDR,B carried out a pilot study in rural Bangladesh (Chowdhury, El Arifeen et al. 2008) to assess the safety and effectiveness of a modified IMCI clinical management guideline for children with severe pneumonia aged 2months - 5 years. The study concluded that appropriate management of severe pneumonia at local level could not only save lives but represent a major cost decrease through reduction of referral, treatment and admission costs. Another research conducted in Pakistan, a randomized equivalency trial revealed that community management of pneumonia through home treatment with high-dose oral amoxicillin was just as effective as current hospital based treatments for severe pneumonia (Hazir et al. 2008). Although all of these findings are very encouraging, none of the study really focused on the immediate outcomes of the IMCI such as improved care seeking, adherence of the health providers and household caregivers to the algorithmic protocol and understanding the barriers and facilitators to the use of this protocol. Moreover, these studies were conducted in controlled research settings and therefore do not provide adequate understanding of the challenges and potential of implementing IMCI in routine health systems. So there is need to carry out research in actual community settings to understand what components of this modified guideline will work in 'real life situations' taking into account all the challenges and constraints faced by health systems of developing countries like Bangladesh.

The primary objectives of our study are to assess adherence of service providers to the modified IMCI guideline for managing severe pneumonia among under-5 children and care-givers' compliance with referral advice given by the health providers after initial care-seeking for under-5 children with severe pneumonia. The secondary objectives will be to measure the resulting changes in the care-seeking pattern for childhood pneumonia due to the introduction of modified IMCI guideline

Two MNCS programme upazilas will be purposively selected for this study in consultation with GoB and partners. The likely districts from where the two upazilas will be selected are Sherpur and Gopalganj. Twenty unions (average population of about 20,000) will be identified from the selected upazilas and randomly assigned to intervention or comparison arms. The intervention and evaluation will continue for 15 months. This will be a cluster randomized trial. Of the 20 selected study unions, 10 unions will be randomly assigned to intervention and 10 to comparison, that is, about 200,000 population (~40,000 households) in each arm. Each geographically delimited union has a Union Health and Family Welfare Centre (UHFWC) and family welfare centre (FWC), servicing the population residing within it. Health providers on the intervention arm will be trained regarding modification in the IMCI guideline. The training will not address any other aspect of the IMCI Training. Training on standard IMCI guideline will only be given to the health providers of both the arms, if not received before. Figure 1 (source: Chowdhury et al 2008) describes the modified and standard IMCI guideline. Under the modified guideline a sick child aged 2-59 months with severe pneumonia should be referred only if it accompanies with danger signs, stridor or any other sign or symptoms of other severe classification. All other children with severe pneumonia should be treated at the first level health facility with oral antibiotic (amoxicillin).

The unions belonging to the comparison arm will continue following the standard IMCI guideline. To measure the outcome of the interventions, the study will involve the following methods: Health facility survey including health providers' survey; extraction and review of health facility service records for provider compliance; routine surveillance for collection of information on care-seeking for childhood pneumonia; tracking and structured interview of severe pneumonia cases seen at facilities Details of the MNCS intervention package and delivery systems can be found in Annex I. All the MNCS upazilas have also already implemented facility-based IMCI.

All drugs in the study protocol are listed drugs of Bangladesh Government. The Study will ensure adequate and timely supplies of all drugs and other minimum essential logistics in all health facilities in the study area. The health facilities will be monitored on an ongoing basis by field supervisors, who will visit each facility once a month.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 2 Months to 5 Years
Eligibility Inclusion Criteria:

- Severe pneumonia with patients of 2 months to 5 years

- Attending first level health care facilities

- In Selected study areas

Exclusion Criteria:

- Any other categories of pneumonia other than severe pneumonia.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Amoxycilline, Cephradine followed by follow up on day 3
Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
Injectable ampicillin followed by urgent referral
Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics

Locations

Country Name City State
Bangladesh Union health facility Gopalganj Gopalganj

Sponsors (2)

Lead Sponsor Collaborator
International Centre for Diarrhoeal Disease Research, Bangladesh UNICEF

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Severe Pneumonia cases approapriately treated as per the Modified IMCI guideline Appropriate management as per modified IMCI guideline denotes Severe pneumonia cases with only chest indrawing and no other danger signs. Such cases will be managed by 1st line oral antiobiotic Amoxicillin by the 1st level health providers. The patient will be asked to come back on 3rd day for follow up when he will be reasessed. If condition improves the antibiotic will be continued for 5 days and if condition deteriorates or remain unchange second line antiobiotic Cephradine will be used. During the treatment if any danger sign appear at any stage the patient will be immediately referred. 15 months
Primary Proportion of severe pneumonia cases complied appropriately with followup advice given by the health care providers Severe pneumonia cases with only chest indrawing and no other danger signs will be managed by 1st level health providers. In this study the appropriate maangement denotes both treatment with antibiotics and complying with the followup advice given by the health care provider. Following antibiotic prescription, the patient will be asked to come back on 3rd day for follow up when S/he will be reasessed. This is an integral part of the modified IMCI guideline. 15 months
Secondary Proportion of childhood pneumonia cases treated by trained service provider Following introduction of modified guideline the proportion of childhood pneumonia cases treated by trained service provider as recognized by Govt of Bangladesh will increase in the intervention area. 15 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years Phase 4
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Terminated NCT02358642 - Drug to Prevent Pneumonia in the Tube Fed Phase 4
Completed NCT01416506 - Community-Acquired Pneumonia (CAP) Surveillance N/A